Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
Juggernaut Confirms District Scale Gold-Rich System on Big One Property Measuring 22 km2 with Assays up to 263.70 g/t AuEq that is Drill Ready, Golden Triangle, B.C.
